FIELD: pharmaceuticals; medicine.
SUBSTANCE: invention relates to the use of biologically active additives containing hydroxyethylammonium methylphenoxyacetate, vitamins: A, D2, E, B1, B2, B5, B9, B12, PP, H, C, calcium, magnesium, iron, selenium, zinc, fluorine, iodine, as a means of increasing the concentration of ferritin in blood serum, 2 tablets 2 times a day with meals for the first 4 weeks, and then a similar repeated course at the 4th month of treatment with basic medicinal products.
EFFECT: invention provides increase of ferritin concentration in human blood serum.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATION MODULATING FERRITIN CONCENTRATION IN BLOOD SERUM | 2020 |
|
RU2749347C1 |
| MEDICATION MODULATING CONCENTRATION OF FERRITIN IN BLOOD SERUM | 2012 |
|
RU2486895C1 |
| A MEANS OF INCREASING THE LEVEL OF LACTOFERRIN IN THE BODY | 2020 |
|
RU2744757C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF ANAEMIA OF CHRONIC DISEASES AND IRON DEFICIENCY ANAEMIA IN PATIENTS WITH INFLAMMATORY JOINT DISEASES | 2024 |
|
RU2825523C1 |
| METHOD OF DIAGNOSING DESTRUCTIVE FORMS OF ACUTE CHOLECYSTITES | 2009 |
|
RU2407017C1 |
| IL-12 AND IL-1A INDUCER | 2014 |
|
RU2564114C1 |
| METHOD FOR RAPID DIAGNOSIS OF THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2789426C1 |
| METHOD FOR PREDICTING THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795093C1 |
| METHOD FOR PREDICTING OUTCOMES OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795095C1 |
| MEDIATION INCREASING LEVEL OF LACTOFERRIN IN ORGANISM | 2012 |
|
RU2486894C1 |
